The effects of temporary intraocular pressure spikes after intravitreal dexamethasone implantation on the retinal nerve fiber layer

References

• Sarao V, Veritti D, Boscia F, Lanzetta P. Intravitreal steroids for the treatment of retinal diseases. The Scientific World Journal. 2014;2014:989501. doi:10.1155/2014/989501
   Web of Science ®Google Scholar
• Kang BS, Chung EY, Yun YP, et al. Inhibitory effects of anti-inflammatory drugs on interleukin-6 bioactivity. Biol Pharm Bull. 2001;24:701–703. doi:10.1248/bpb.24.701
   PubMed Web of Science ®Google Scholar
• Wilson CA, Berkowitz BA, Sato Y, Ando N, Handa JT, de Juan E Jr. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol. 1992;110:1155–1159.
   PubMed Web of Science ®Google Scholar
• Fischer S, Renz D, Schaper W, Karliczek GF. In vitro effects of dexamethasone on hypoxia-induced hyperpermeability and expression of vascular endothelial growth factor. Eur J Pharmacol. 2001;411:231–243.
   PubMed Web of Science ®Google Scholar
• Haghjou N, Soheilian M, Abdekhodaie MJ. Sustained release intraocular drug delivery devices for treatment of uveitis. J Ophthalmic Vis Res. 2011;6:317–329.
   PubMedGoogle Scholar
• Chang-Lin JE, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52:80–86. doi:10.1167/iovs.10-5285
   PubMed Web of Science ®Google Scholar
• Haller JA, Bandello F, Belfort R Jr., et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(1134–46):e3. doi:10.1016/j.ophtha.2010.03.032
   Web of Science ®Google Scholar
• Lowder C, Belfort R Jr., Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129:545–553. doi:10.1001/archophthalmol.2010.339
   PubMed Web of Science ®Google Scholar
• Li X, Wang N, Liang X, et al. Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients: randomized, sham-controlled, multicenter study. Graefe’s Arch Clin Exp Ophthalmol. 2018;256:59–69. doi:10.1007/s00417-017-3831-6
   Web of Science ®Google Scholar
• Kuppermann BD, Goldstein M, Maturi RK, et al. Dexamethasone intravitreal implant as adjunctive therapy to ranibizumab in neovascular age-related macular degeneration: a multicenter randomized controlled trial. Ophthalmologica J Int d’ophtalmologie Int J Ophthalmol Z fur Augenheilkunde. 2015;234:40–54. doi:10.1159/000381865
   Web of Science ®Google Scholar
• Capone A Jr., Singer MA, Dodwell DG, et al. Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (Shasta study). Retina. 2014;34:342–351. doi:10.1097/IAE.0b013e318297f842
   PubMed Web of Science ®Google Scholar
• Boyer DS, Yoon YH, Belfort R Jr., et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121:1904–1914. doi:10.1016/j.ophtha.2014.04.024
   PubMed Web of Science ®Google Scholar
• Quigley HA, McKinnon SJ, Zack DJ, et al. Retrograde axonal transport of BDNF in retinal ganglion cells is blocked by acute IOP elevation in rats. Invest Ophthalmol Vis Sci. 2000;41:3460–3466.
   PubMed Web of Science ®Google Scholar
• Boland MV, Ervin AM, Friedman DS, et al. Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the U.S. preventive services task force. Ann Int Med. 2013;158:271–279. doi:10.7326/0003-4819-158-4-201302190-00008
   PubMed Web of Science ®Google Scholar
• Bucolo C, Gozzo L, Longo L, Mansueto S, Vitale DC, Drago F. Long-term efficacy and safety profile of multiple injections of intravitreal dexamethasone implant to manage diabetic macular edema: a systematic review of real-world studies. J Pharmacol Sci. 2018;138:219–232. doi:10.1016/j.jphs.2018.11.001
   PubMed Web of Science ®Google Scholar
• Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007;125:309–317. doi:10.1001/archopht.125.3.309
   PubMed Web of Science ®Google Scholar
• Eter N, Mohr A, Wachtlin J, Feltgen N, Shirlaw A, Leaback R. Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical trial. Graefe’s Arch Clin Exp Ophthalmol. 2017;255:77–87. doi:10.1007/s00417-016-3431-x
   PubMed Web of Science ®Google Scholar
• Korobelnik JF, Kodjikian L, Delcourt C, et al. Two-year, prospective, multicenter study of the use of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in the clinical setting in France. Graefe’s Arch Clin Exp Ophthalmol. 2016;254:2307–2318. doi:10.1007/s00417-016-3394-y
   Web of Science ®Google Scholar
• Burgoyne CF, Downs JC, Bellezza AJ, Suh JK, Hart RT. The optic nerve head as a biomechanical structure: a new paradigm for understanding the role of IOP-related stress and strain in the pathophysiology of glaucomatous optic nerve head damage. Prog Retin Eye Res. 2005;24:39–73. doi:10.1016/j.preteyeres.2004.06.001
   PubMed Web of Science ®Google Scholar
• Kersey T, Clement CI, Bloom P, Cordeiro MF. New trends in glaucoma risk, diagnosis & management. Indian J Med Res. 2013;137:659–668.
   Web of Science ®Google Scholar
• De Moraes CG, Liebmann JM, Levin LA. Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma. Prog Retin Eye Res. 2017;56:107–147. doi:10.1016/j.preteyeres.2016.10.001
   PubMed Web of Science ®Google Scholar
• Phu J, Khuu SK, Yapp M, Assaad N, Hennessy MP, Kalloniatis M. The value of visual field testing in the era of advanced imaging: clinical and psychophysical perspectives. Clin Exp Optometry. 2017;100:313–332. doi:10.1111/cxo.2017.100.issue-4
   PubMed Web of Science ®Google Scholar
• Leung CK. Diagnosing glaucoma progression with optical coherence tomography. Curr Opin Ophthalmol. 2014;25:104–111. doi:10.1097/ICU.0000000000000024
   PubMed Web of Science ®Google Scholar
• Leung CK, Cheung CY, Weinreb RN, et al. Retinal nerve fiber layer imaging with spectral-domain optical coherence tomography: a variability and diagnostic performance study. Ophthalmology. 2009;116:1257–63,63 e1–e2. doi:10.1016/j.ophtha.2009.04.013
   Web of Science ®Google Scholar
• Leung CK, Lam S, Weinreb RN, et al. Retinal nerve fiber layer imaging with spectral-domain optical coherence tomography: analysis of the retinal nerve fiber layer map for glaucoma detection. Ophthalmology. 2010;117:1684–1691. doi:10.1016/j.ophtha.2010.01.026
   PubMed Web of Science ®Google Scholar
• Clark AF, Wordinger RJ. The role of steroids in outflow resistance. Exp Eye Res. 2009;88:752–759. doi:10.1016/j.exer.2008.10.004
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. Jama. 2014;311:1901–1911. doi:10.1001/jama.2014.3192
   PubMed Web of Science ®Google Scholar
• Kramar M, Vu L, Whitson JT, He YG. The effect of intravitreal triamcinolone on intraocular pressure. Curr Med Res Opin. 2007;23:1253–1258. doi:10.1185/030079907X187946
   PubMed Web of Science ®Google Scholar
• Unsal E, Eltutar K, Sultan P, Gungel H. The efficiency of intravitreal dexamethasone implants in the treatment of macular edema secondary to retinal vein occlusion. J Ocul Pharmacol Ther. 2015;31:350–356. doi:10.1089/jop.2014.0141
   Web of Science ®Google Scholar
• Li H, Healey PR, Tariq YM, Teber E, Mitchell P. Symmetry of optic nerve head parameters measured by the heidelberg retina tomograph 3 in healthy eyes: the blue mountains eye study. Am J Ophthalmol. 2013;155(518–23):e1. doi:10.1016/j.ajo.2012.09.019
   Web of Science ®Google Scholar
• Dalgliesh JD, Tariq YM, Burlutsky G, Mitchell P. Symmetry of retinal parameters measured by spectral-domain OCT in normal young adults. J Glaucoma. 2015;24:20–24. doi:10.1097/IJG.0b013e318287ac2f
   PubMed Web of Science ®Google Scholar